Cargando…

Symptoms in first-degree relatives of patients with rheumatoid arthritis: evaluation of cross-sectional data from the symptoms in persons at risk of rheumatoid arthritis (SPARRA) questionnaire in the PRe-clinical EValuation of Novel Targets in RA (PREVeNT-RA) Cohort

BACKGROUND: First-degree relatives (FDRs) of people with rheumatoid arthritis (RA) have a fourfold increased risk of developing RA. The Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire was developed to document symptoms in persons at risk of RA. The aims of this study were...

Descripción completa

Detalles Bibliográficos
Autores principales: Costello, R. E., Humphreys, J. H., Sergeant, J. C., Haris, M., Stirling, F., Raza, K., van Schaardenburg, D., Bruce, Ian N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8356426/
https://www.ncbi.nlm.nih.gov/pubmed/34380557
http://dx.doi.org/10.1186/s13075-021-02593-w
_version_ 1783736942673788928
author Costello, R. E.
Humphreys, J. H.
Sergeant, J. C.
Haris, M.
Stirling, F.
Raza, K.
van Schaardenburg, D.
Bruce, Ian N.
author_facet Costello, R. E.
Humphreys, J. H.
Sergeant, J. C.
Haris, M.
Stirling, F.
Raza, K.
van Schaardenburg, D.
Bruce, Ian N.
author_sort Costello, R. E.
collection PubMed
description BACKGROUND: First-degree relatives (FDRs) of people with rheumatoid arthritis (RA) have a fourfold increased risk of developing RA. The Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire was developed to document symptoms in persons at risk of RA. The aims of this study were (1) to describe symptoms in a cohort of FDRs of patients with RA overall and stratified by seropositivity and elevated CRP and (2) to determine if patient characteristics were associated with symptoms suggestive of RA. METHODS: A cross-sectional study of FDRs of patients with RA, in the PREVeNT-RA study, who completed a study questionnaire, provided a blood sample measured for rheumatoid factor, anti-CCP and CRP and completed the SPARRA questionnaire. Moderate/severe symptoms and symmetrical, small and large joint pain were identified and described. Symptoms associated with both seropositivity and elevated CRP were considered suggestive of RA. Logistic regression was used to determine if symptoms suggestive of RA were associated with patient characteristics. RESULTS: Eight hundred seventy participants provided all data, 43 (5%) were seropositive and 122 (14%) had elevated CRP. The most frequently reported symptoms were sleep disturbances (20.3%) and joint pain (17.9%). Symmetrical and small joint pain were 11.3% and 12.8% higher, respectively, in those who were seropositive and 11.5% and 10.7% higher in those with elevated CRP. In the logistic regression model, seropositivity, older age and feeling depressed were associated with increased odds of small and symmetrical joint pain. CONCLUSIONS: This is the first time the SPARRA questionnaire has been applied in FDRs of patients with RA and has demonstrated that the presence of symmetrical and small joint pain in this group may be useful in identifying people at higher risk of developing RA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-021-02593-w.
format Online
Article
Text
id pubmed-8356426
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-83564262021-08-11 Symptoms in first-degree relatives of patients with rheumatoid arthritis: evaluation of cross-sectional data from the symptoms in persons at risk of rheumatoid arthritis (SPARRA) questionnaire in the PRe-clinical EValuation of Novel Targets in RA (PREVeNT-RA) Cohort Costello, R. E. Humphreys, J. H. Sergeant, J. C. Haris, M. Stirling, F. Raza, K. van Schaardenburg, D. Bruce, Ian N. Arthritis Res Ther Research Article BACKGROUND: First-degree relatives (FDRs) of people with rheumatoid arthritis (RA) have a fourfold increased risk of developing RA. The Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire was developed to document symptoms in persons at risk of RA. The aims of this study were (1) to describe symptoms in a cohort of FDRs of patients with RA overall and stratified by seropositivity and elevated CRP and (2) to determine if patient characteristics were associated with symptoms suggestive of RA. METHODS: A cross-sectional study of FDRs of patients with RA, in the PREVeNT-RA study, who completed a study questionnaire, provided a blood sample measured for rheumatoid factor, anti-CCP and CRP and completed the SPARRA questionnaire. Moderate/severe symptoms and symmetrical, small and large joint pain were identified and described. Symptoms associated with both seropositivity and elevated CRP were considered suggestive of RA. Logistic regression was used to determine if symptoms suggestive of RA were associated with patient characteristics. RESULTS: Eight hundred seventy participants provided all data, 43 (5%) were seropositive and 122 (14%) had elevated CRP. The most frequently reported symptoms were sleep disturbances (20.3%) and joint pain (17.9%). Symmetrical and small joint pain were 11.3% and 12.8% higher, respectively, in those who were seropositive and 11.5% and 10.7% higher in those with elevated CRP. In the logistic regression model, seropositivity, older age and feeling depressed were associated with increased odds of small and symmetrical joint pain. CONCLUSIONS: This is the first time the SPARRA questionnaire has been applied in FDRs of patients with RA and has demonstrated that the presence of symmetrical and small joint pain in this group may be useful in identifying people at higher risk of developing RA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13075-021-02593-w. BioMed Central 2021-08-11 2021 /pmc/articles/PMC8356426/ /pubmed/34380557 http://dx.doi.org/10.1186/s13075-021-02593-w Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Costello, R. E.
Humphreys, J. H.
Sergeant, J. C.
Haris, M.
Stirling, F.
Raza, K.
van Schaardenburg, D.
Bruce, Ian N.
Symptoms in first-degree relatives of patients with rheumatoid arthritis: evaluation of cross-sectional data from the symptoms in persons at risk of rheumatoid arthritis (SPARRA) questionnaire in the PRe-clinical EValuation of Novel Targets in RA (PREVeNT-RA) Cohort
title Symptoms in first-degree relatives of patients with rheumatoid arthritis: evaluation of cross-sectional data from the symptoms in persons at risk of rheumatoid arthritis (SPARRA) questionnaire in the PRe-clinical EValuation of Novel Targets in RA (PREVeNT-RA) Cohort
title_full Symptoms in first-degree relatives of patients with rheumatoid arthritis: evaluation of cross-sectional data from the symptoms in persons at risk of rheumatoid arthritis (SPARRA) questionnaire in the PRe-clinical EValuation of Novel Targets in RA (PREVeNT-RA) Cohort
title_fullStr Symptoms in first-degree relatives of patients with rheumatoid arthritis: evaluation of cross-sectional data from the symptoms in persons at risk of rheumatoid arthritis (SPARRA) questionnaire in the PRe-clinical EValuation of Novel Targets in RA (PREVeNT-RA) Cohort
title_full_unstemmed Symptoms in first-degree relatives of patients with rheumatoid arthritis: evaluation of cross-sectional data from the symptoms in persons at risk of rheumatoid arthritis (SPARRA) questionnaire in the PRe-clinical EValuation of Novel Targets in RA (PREVeNT-RA) Cohort
title_short Symptoms in first-degree relatives of patients with rheumatoid arthritis: evaluation of cross-sectional data from the symptoms in persons at risk of rheumatoid arthritis (SPARRA) questionnaire in the PRe-clinical EValuation of Novel Targets in RA (PREVeNT-RA) Cohort
title_sort symptoms in first-degree relatives of patients with rheumatoid arthritis: evaluation of cross-sectional data from the symptoms in persons at risk of rheumatoid arthritis (sparra) questionnaire in the pre-clinical evaluation of novel targets in ra (prevent-ra) cohort
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8356426/
https://www.ncbi.nlm.nih.gov/pubmed/34380557
http://dx.doi.org/10.1186/s13075-021-02593-w
work_keys_str_mv AT costellore symptomsinfirstdegreerelativesofpatientswithrheumatoidarthritisevaluationofcrosssectionaldatafromthesymptomsinpersonsatriskofrheumatoidarthritissparraquestionnaireinthepreclinicalevaluationofnoveltargetsinrapreventracohort
AT humphreysjh symptomsinfirstdegreerelativesofpatientswithrheumatoidarthritisevaluationofcrosssectionaldatafromthesymptomsinpersonsatriskofrheumatoidarthritissparraquestionnaireinthepreclinicalevaluationofnoveltargetsinrapreventracohort
AT sergeantjc symptomsinfirstdegreerelativesofpatientswithrheumatoidarthritisevaluationofcrosssectionaldatafromthesymptomsinpersonsatriskofrheumatoidarthritissparraquestionnaireinthepreclinicalevaluationofnoveltargetsinrapreventracohort
AT harism symptomsinfirstdegreerelativesofpatientswithrheumatoidarthritisevaluationofcrosssectionaldatafromthesymptomsinpersonsatriskofrheumatoidarthritissparraquestionnaireinthepreclinicalevaluationofnoveltargetsinrapreventracohort
AT stirlingf symptomsinfirstdegreerelativesofpatientswithrheumatoidarthritisevaluationofcrosssectionaldatafromthesymptomsinpersonsatriskofrheumatoidarthritissparraquestionnaireinthepreclinicalevaluationofnoveltargetsinrapreventracohort
AT razak symptomsinfirstdegreerelativesofpatientswithrheumatoidarthritisevaluationofcrosssectionaldatafromthesymptomsinpersonsatriskofrheumatoidarthritissparraquestionnaireinthepreclinicalevaluationofnoveltargetsinrapreventracohort
AT vanschaardenburgd symptomsinfirstdegreerelativesofpatientswithrheumatoidarthritisevaluationofcrosssectionaldatafromthesymptomsinpersonsatriskofrheumatoidarthritissparraquestionnaireinthepreclinicalevaluationofnoveltargetsinrapreventracohort
AT bruceiann symptomsinfirstdegreerelativesofpatientswithrheumatoidarthritisevaluationofcrosssectionaldatafromthesymptomsinpersonsatriskofrheumatoidarthritissparraquestionnaireinthepreclinicalevaluationofnoveltargetsinrapreventracohort